Arctos Medical, which is developing gene therapies to treat sight loss, had raised $8.1m from investors including Novartis two years ago.

Pharmaceutical firm Novartis acquired one of its portfolio companies, Switzerland-based ocular therapeutics developer Arctos Medical, for an undisclosed amount today.

Founded in 2012, Arctos is working on optogenetics-based adeno-associated virus gene therapies to treat diseases that involve photoreceptor loss – which causes blindness – such as inherited retinal dystrophies and age-related macular degeneration.

The company was incubated at ND Capital, the venture capital firm then known as NanoDimension, and secured $8.1m in a December 2019 series A round led by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn